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Neuropeptides are signaling molecules of intermediate size that are involved in neu-
rotransmission and endocrine regulation. Complete monitoring of neuropeptides using
neuropeptidomics approaches remains an important goal for describing targeted physio-
logical regulation pathways. Considerable effort has been expended, particularly in terms
of  technique and methodology development, to extend the scope of neuropeptidomics.
The capability of peptide characterization has been gradually improved, thus responding
to  increasing demands for broad detection and determination of various peptides. In thisree shrews review, we discuss some achievements for the improvement of peptide identiﬁcation cover-
age  and their application for brain diseases and studying consequences of drug applications.
©  2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). This is an open access article under the CC BY license
tidome becomes highly desirable in many  cases for example in.  Introduction
he role of neuropeptides continues to receive great attention
n the ﬁelds of basic neuroscience as well as clinical and phar-
aceutical research. As molecules of a size falling between
roteins and classical neurotransmitters, neuropeptides carry
ut speciﬁc functions in diverse physiological processes and
athways [1]. For example, neuropeptides can act on G-protein
oupled receptors, generating intracellular cascades and sub-
equently leading to response of cells, microcircuits, organs
nd ultimately behaviors. They are indispensable for species
rom worms to humans, for example in the regulation of
leep, food-intake, sexual function and reward processing.
mportantly, neuropeptides seem to never work alone, but
ne generally ﬁnds that a set of neuropeptides, rather than
 single neuropeptide, is involved in a given brain disorder
r physiological pathway [2,3]. Without doubt, a complete
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characterization of the neuropeptidome will be of great inter-
est for studying brain functions, discovering biomarkers or
characterizing drug effects.
Mass spectrometry (MS)-based neuropeptidomics, as a
sub-branch of proteomics, has now emerged as the method
of choice for high throughput sequencing of endogenous
neuropeptides in biological samples [4–6]. Compared to pro-
teomics that focuses on characterization of digested peptides,
neuropeptidomics shares many  technical implementation
aspects but also clearly requires some different methodologies
due to the biological and chemical properties of endogenous
peptides. As particular neuropeptides can have distinct bioac-
tive effects, even if they are derived from the same precursor,
the characterization of every member of an entire neuropep-the discovery of biomarkers. In addition, many  neuropeptides
have long sequences containing often more  than thirty amino
acids, and exhibit low informative tandem MS  spectra as
 European Proteomics Association (EuPA). This is an open access
y/3.0/).
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well as high hydrophobicity. These features inevitably present
substantial challenges upon many  procedures such as pep-
tide extraction, separation, identiﬁcation and quantitation [7],
which in turn has stimulated technical and methodologi-
cal development efforts for more  powerful neuropeptidomics
approaches [8,9].
In the last decade, extensive efforts have been expended
to improve the peptide identiﬁcation coverage by developing
novel methods and have yielded exciting advances [10–17].
Current integrated peptidomics approaches allow the identiﬁ-
cation of hundreds of prohormone-derived peptides even from
tiny amounts of body ﬂuid or tissue samples [15,18,19]. The
species investigated have also been extended from the com-
mon  laboratory animals such as mice and rats to uncommon
species including tree shrew [14], bee [3] and crab [20]. Very
recently, the application of quantitative neuropeptidomics has
received increased interest for characterizing neuropeptide
changes in studies of central nervous system diseases or
drugs. This review reports advances in neuropeptidomics,
with a particular focus on the improvement of neuropeptide
identiﬁcation and its biological applications.
2.  Increased  peptide  identiﬁcation  coverage
in  neuropeptidomics
2.1.  Sample  treatment
Sample treatment is an initial but crucial step that remark-
ably affects peptide identiﬁcation coverage. Neuropeptides,
as well as various proteins, are subject to rapid proteolysis
under room temperature. This degeneration results in the
decrease or even disappearance of neuropeptides from tissue
samples. Moreover, the degeneration of proteins produces a
large number of peptide fragments. The presence of these frag-
ments complicates the LC–MS/MS analysis because fragments
compete with native neuropeptides during sample extraction,
peptide ionization and fragmentation. Previous studies have
shown that preparation of brain samples from live animals
after euthanasia without deactivation of enzymes results in
the production of a large amount of neuropeptide fragments.
Different techniques, such as snap-freezing, microwave heat-
ing and laser heating, have been developed to reduce peptide
degeneration [21,22]. While snap-freezing is convenient to
use, the stability of the treated tissue is generally poor, and
often insufﬁcient for quantitative analysis. In contrast, heat-
ing using microwave or laser allows the production of high
quality stabilized samples because enzymes are permanently
deactivated, protecting endogenous peptides from proteoly-
sis. Particularly, the laser heating system is easy to conduct
and maintains the morphology of the tissue much better
than microwave heating. Intact morphology is useful for pre-
cise extraction of brain regions of interest, particularly when
relatively small nuclei are targeted. Peptide extraction and
subsequent treatment is another procedure that affects iden-
tiﬁcation rate in neuropeptidomics. Brain samples contain
a vast number of peptides, which have extremely different
abundances, lengths, hydrophobicities and chemical prop-
erties. The use of different solvents and/or procedures has
pronounced effects on peptide proﬁles detectable in brain 3 ( 2 0 1 4 ) 273–279
tissue samples. The extraction or preservation of diverse neu-
ropeptides in a single solution, for example the commonly
used aqueous buffers [2,4], results in a substantial loss of pep-
tides [23]. Similar phenomena were found during direct mixing
of different solutions in a multi-stage extraction procedure
[7]. Alternatively, a mixing on column strategy, which seri-
ally loads organic and aqueous extracts, allows simultaneous
retention of a large number of hydrophilic and hydrophobic
peptides on the column, consequently increasing the peptide
identiﬁcation rate [7].
2.2.  Targeted  and  directed  LC–MS
High accuracy MS  has become a method of choice in neuropep-
tidomics, mainly due to the presence of many  long peptides
in the central nervous system. The use of high accuracy mea-
surements of both precursor and productions can provide an
informative and promising approach for peptide sequencing,
thus facilitating the improvement in the assignment of frag-
ment ion series [15,24,25]. However, the use of high resolution
MS is only part of the solution, because the overall peptide
identiﬁcation coverage critically depends on the capability of
a method for the fragmentation of low abundant peptides.
In a typical LC–MS/MS analysis, many  hundreds or even
thousands of peptide features can be detected in MS1, leading
crowded peptide peaks in a limited elution time (Fig. 1A). Tens
or even hundreds of peptide features are thus present within
several seconds (Fig. 1B), which far exceeds the fragmenta-
tion capability of a mass spectrometer, in particular for those
operated with FT-MS/MS mode. In a common data dependent
LC–MS/MS analysis, peptides of highest intensities are submit-
ted to fragmentation within an acceptable scan period. This
makes the sequencing of low abundant peptides in a single
or repeated data-dependent LC–MS/MS analysis difﬁcult due
to the limited scan speed of current LC–MS/MS systems, even
if precautions like dynamic exclusion are used [26]. To  deal
with these issues, directed or targeted LC–MS/MS have been
developed to guide the features into fragmentation, by which
high quality tandem MS spectra could be acquired for a vast
number of peptides or desired peptides.
A targeted LC–MS/MS analysis strategy allows the MS/MS
analysis on precursor ions of interest during analysis of com-
plex biological samples (Fig. 2). As only speciﬁed ions are
selected for fragmentation, MS/MS parameters, for example
resolution and maximum accumulation time in FT-MS sys-
tems, can be optimized and thus increase the capability of
generation of high quality tandem MS  spectra. Illustrating
this advantage, targeted LC–MS/MS analysis has been applied
in the tree shrew neuropeptidome analysis to screen neu-
ropeptides that are identical to their counterparts in one or
more  related mammalian species [14]. Inclusion mass lists
of previously reported peptides identiﬁed from other species
including mice, rats, and humans were thus submitted to
LC–FT-MS/MS analysis. The application of targeted LC–MS/MS
analysis allowed the identiﬁcation of several classical neu-
ropeptides, despite the fact that they exist in the tree shrew
brain at low concentrations.
Compared to targeted LC–MS/MS analysis, directed pep-
tide sequencing strategy facilitates a comprehensive MS/MS
analysis on non-redundant precursor ions and thus increases
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Fig. 1 – Representative LC–MS chromatogram of a brain extract. (A) A large number of peptide features can be detected
within a 80-min gradient. (B) A representative MS1 spectrum of peptide features collected within a 10 s interval.
Fig. 2 – Schematic illustration of targeted and directed LC–MS/MS analysis for a sample containing features with similar
r arge
t
s
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petention times on an LC column. Rt: retention time, CSD: ch
he depth of analysis [26,27]. A directed LC–MS/MS analy-
is is conducted using an inclusion mass list of precursor
ons which can be prepared based on analysis of the full
can LC–MS data that are acquired from the same sam-
le in advance using the identical LC elution proﬁle. The state dependent.
precursor ions are selected according to retention time and
intensities of peptides in LC–MS analysis. For example, a pro-
teomics study has demonstrated that when inclusion lists
are divided into segments of 3–5 min, the number of possi-
ble target masses can increase to as many  as 3000 in a 1-h LC
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gradient, leading to a signiﬁcant increase in the identiﬁcation
coverage [26].
Charge state directed (CSD) LC–MS/MS analysis is a vari-
ant of commonly used directed LC–MS/MS analysis strategy,
which is performed by scanning peptides according to their
charge states rather than using dedicated inclusion mass
lists. Although a directed LC–MS/MS analysis can signiﬁcantly
increase the capability of detection of low abundant peptides,
some peptides are still unable be sequenced if too many  other
peptides co-elute at the same retention time. This is particular
true when using the low scan speed instrument such as FT-MS
spectrometers, which has lower sensitivity and slower scan
speed than low resolution MS/MS  conducted in other detectors
such as ion traps [28]. By comparison, CSD LC–MS/MS analysis
demonstrates its advantage if just the peptides of a speciﬁed
charge state(s) are fragmented in a LC run. As the targeted
precursor ions are much reduced, optimized MS/MS param-
eters can be applied for acquisition of high quality tandem
MS  spectra for low abundant peptides. After the LC–MS/MS
analyses of peptides of all desired charge states, the data
from a given sample are pooled for database search. Although
repeated LC–MS/MS analyses are required, CSD–LC–MS/MS
analysis reduces the time needed for generation of inclusion
lists in a commonly used targeted LC–MS/MS analysis. The
application of such approach allows 206 peptides on average
to be identiﬁed from mouse prohormones in a single brain
sample that was extracted using 15 l solutions per 1 mg  of tis-
sue. The cumulative number of peptides identiﬁed from three
brain samples reached a value of 272 [18].
2.3.  Complementary  fragmentation  approaches
Collision induced dissociation (CID) has become the method
of choice for peptide identiﬁcation in neuropeptidomics. Yet,
identiﬁcations of the intact forms of long peptides are still dif-
ﬁcult even with high resolution MS. Now this issue has been
alleviated due to the implementation of alternative fragmen-
tation techniques such as high energy collision dissociation
(HCD) and electron transfer dissociation (ETD). Compared to
CID, HCD offers more  informative tandem MS  spectra, thus
increasing the peptide identiﬁcation. ETD is a highly charge
state-dependent fragmentation technique and is more  suited
for precursor charge states higher than 2, which is use-
ful for the identiﬁcation of large neuropeptides. Because of
the complementarities, the combined use of ETD and other
fragmentation techniques, particularly ETD and HCD, has
remarkably improved the identiﬁcation capability of peptides
in the top-down sequencing strategy [29].
2.4.  Neuropeptidomics  of  uncommon  mammalian
species
Although massive progress in neuropeptidomics has been
achieved on common laboratory mammalian species, the
analysis of complete neuropeptidome of uncommon species
remains challenging because of the lack of proteome for direct
database search. When the genome available for a particu-
lar species, the prohormone sequences can be predicted from
the genome and consequently a database can be created for
sequencing peptides from MS  data, as has been done 3 ( 2 0 1 4 ) 273–279
for example in Apis mellifera [30] and Zebra ﬁnch [31]. For
some species without a fully sequenced genome, the iden-
tiﬁcation of peptides mostly depends on de-novo sequencing,
which is normally done at low throughput and is more  suited
for short peptides or peptides of highly informative MS  spec-
tra. To deal with issue, databases can be developed based
on the collection of prohormones from related species. Such
a database can be used for direct peptide sequencing or
homology search, which has been successfully conducted for
example in tree shrews. Tree shrews are similar in size to
rats but phylogenetically very close to primates [32,33]. To
date, neither a complete genome nor proteome is available
for this species. Due to the highly conserved nature of neu-
ropeptides [34], the majority of neuropeptides in tree shrews
have identical or similar sequences to those in related mam-
malian species. Based on this principle, FT-MS/MS data from
tree shrew brain were search against a predicted peptide
database, which consists of predicted peptides from prohor-
mones collected from related species in the Euarchontaglires
clade. Using this approach, 92 peptides that have identical
sequences to those from one or more  other species can be
directly sequenced using database search. Meanwhile, 15 pep-
tides with substituted amino acid residues were identiﬁed
using homology search based on de novo sequencing results.
3.  Neuropeptidomics  for  the  investigation
of  CNS  diseases  and  drug  responses
Neuropeptides have been commonly quantiﬁed using
immunoassay or radioimmunoassay [35,36] in the discov-
ery of markers of brain diseases or in the interpretation
of pharmaceutical mechanisms. However, this procedure
is time-consuming, limited to known peptides, and it is
often impossible to distinguish between similar peptides.
Moreover, the throughput of immunoassays is extremely
low, and limited to one or several peptides in practice. In
contrast, quantitative neuropeptidomics can simultaneously
provide a complete image  of many  peptides in the brain
region of interest and thus has been increasingly used. Mass
spectrometric approaches offer several advantages including
higher sensitivity and throughput compared to traditional
methods [37–42].
The performance of quantitative neuropeptidomics is
highly approach-dependent. Currently, selected reaction
monitoring (SRM), chemical labeling, label-free monitoring
and are the three most commonly used approaches for
quantify peptides [43–45]. SRM-based quantitation was ini-
tially developed for the analysis of small molecules, but now
it has been adapted for the quantitation of a large num-
ber of peptides with monitoring of multiple transitions for
each feature. SRM-based analysis is highly sensitive and is
thus expected to be increasingly used in neuropeptidomics,
although it requires extra informatics work to determine the
transitions of tens to thousands of peptides and, correction
of the retention time to make the quantitation reliable across
different samples or different columns. Chemical labeling is
a widely used method for relative quantitation. While the
labeling performance depends on the agent used and chemi-
cal properties of peptides, the use of chemical tags, such as
 c s 3
t
l
s
m
b
p
i
n
u
o
e
d
d
t
e
a
s
t
D
N
a
s
r
(
i
[
d
c
g
s
p
t
r
v
a
o
a
w
g
i
a
s
d
a
r
d
m
b
f
t
t
a
n
m
i
r
n
r
[3] Brockmann A, Annangudi SP, Richmond TA, Ament SA, Xiee u  p a o p e n p r o t e o m i
rimethylammoniumbutyryl (TMAB) [46] and N,N-dimethyl
eucines [47], considerably enhances the precision and even
ensitivity of quantitation. Compared to chemical labeling
ethods, label-free quantitation is substantially less precise
ut offers broader scope for monitoring various peptides, in
articular those exhibiting relatively large changes between
nvestigated conditions. Nevertheless, because of its conve-
ience and low-cost, label-free quantitation is increasingly
sed for monitoring peptide changes during drug application
r disease diagnostics.
The application of quantitative neuropeptidomics has gen-
rated exciting achievements in the research of various brain
iseases. For example, a neuropeptidomics approach has
emonstrated its power in detecting, identifying, and simul-
aneously quantifying the levels of a considerable number of
ndogenous peptides, including known and novel ones in an
nimal model of Parkinson disease [2], revealing alterations of
ecretogranin-1, somatostatin, prodynorphin, and cholecys-
okinin peptides in the striatum of the animals affected by
opamine depletion in an experimental model of the disease.
europeptidomics studies using labeling techniques have
lso been performed on animal models of obesity, and have
hown that a number of hypothalamic peptides including neu-
opeptide Y, enkephalins, Melanin-concentrating hormone
MCH), and -melanocyte-stimulating hormone (-MSH) are
nvolved in the regulation of body-weight and food-intake
46,48].
The application of neuropeptidomics in the ﬁeld of CNS
rug research has promoted the discovery of diverse neuro-
hemicals that are involved in neuronal circuits. For example,
eneral anesthesia during a neurosurgical procedure was
hown to strongly impact the neuropeptide brain system,
otentially reinforcing effects of general anesthesia. Along
hese lines, Fouillen and colleagues have performed a neu-
opeptidomics study in tree shrew hypothalamus during
olatile isoﬂurane/nitrous oxide anesthesia administrated
ccompanying a neurosurgical procedure. An up-regulation
f 12 hypothalamic peptides was detect, 6 from opioid family
nd 6 from other families [49], revealing novel neuropeptides
hose levels are affected during the surgical procedure under
eneral anesthesia.
Peptidomics analyses in rats have demonstrated the
nvolvement of peptides in the process of neural adaptation
fter repeatedly exposure of amphetamine, a psychological
timulant [50]. The peptidome analysis was performed for
ifferent brain areas like dorsal striatum (dSTR), nucleus
ccumbens (NAcc) and prefrontal cortex (PFC) of rats that
eceived amphetamine over 19 days. Among the 150–300 peaks
etected using MALDI-MS, peptides like neuromodulin, stath-
in  or thymosin beta-4 were found to be signiﬁcantly altered
y the drug treatment. These marker peptides are derived
rom proteins that have been recognized for their role in
he neuroadaptation and drug-induced behavioral sensitiza-
ion. These results show that after chronic treatment with
mphetamine there are chemical changes in neuronal orga-
ization and pathways not only related to dopamine in the
esolimbic system. In general, the behavioral sensitizations associated with complex chemical adaptations in the brain
eward circuit in pathways that regulate energy/metabolism,
eurotransmission and neuroprotection. ( 2 0 1 4 ) 273–279 277
Neuropeptidomics has also produced novel insights related
to neurochemical alterations following chronic nicotine treat-
ment [51]. The chronic use of nicotine, the main psychoactive
ingredient of tobacco, alters diverse physiological processes
and consequently generates physical dependence. The treat-
ment with chronic nicotine for three months led to moderate
changes in the levels of endogenous peptides, including not
only ﬁve enkephalin opioid peptides up-regulated, but also 9
non-opioid peptides, in the dorsal striatum. The regulation of
chronic nicotine treatment on the multiple peptidergic sys-
tems implies the involvement of addictive, metabolism and
endocrine pathways in the preoccupation/craving phase of
drug dependence. This ﬁnding linked for the ﬁrst time other
classes of neuropeptides with the chronic nicotine treatment
and may reﬂect a neurochemical adaptation or compensation
system for deﬁcit of other neurotransmitter like dopamine,
acetylcholine or serotonin.
4.  Conclusion  and  future  perspectives
After more  than one decade development, MS-based neu-
ropeptidomics has greatly extended its scope for monitoring
endogenous peptides present in diverse species. Continuous
efforts continue to be expended for the identiﬁcation and
quantitation of peptides, in particular those of long sequence
and/or low abundance. Following the advances of neuropep-
tidomics, the qualitative and quantitative approaches will
be transferred to various biological ﬁelds. Its application is
expected to yield insights in the understanding of neurochem-
ical communication of neurons in various behaviors such as
food-intake, sleep, sexual function, learning and memory.  As
neuropeptides are crucial molecules involved in various phys-
iological processes, they at the same time represent important
candidates of biomarkers for diseases and potential drug
targets for therapeutic interventions. Taken together, many
exciting achievements can be anticipated in the near future in
neuropeptidomics applications in the central nervous system.
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